Mostrar el registro sencillo del ítem
Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone
| dc.rights.license | open | en_US |
| dc.contributor.author | BAYLE, Franck | |
| hal.structure.identifier | Institut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA] | |
| dc.contributor.author | TESSIER, Arnaud | |
| dc.contributor.author | BOUJU, Sophie | |
| hal.structure.identifier | Institut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA] | |
| dc.contributor.author | MISDRAHI, David | |
| dc.date.accessioned | 2025-05-05T08:04:25Z | |
| dc.date.available | 2025-05-05T08:04:25Z | |
| dc.date.issued | 2015-09-16 | |
| dc.identifier.issn | 1177-889X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/206534 | |
| dc.description.abstractEn | Background: Maintaining antipsychotic therapy in psychosis is important in preventing relapse. Long-acting depot preparations can prevent covert non-adherence and thus potentially contribute to better patient outcomes. In this observational survey the main objective is to evaluate medication adherence and its determinants for oral treatment in a large sample of patients with psychosis. Methods: In this cross-sectional survey medication adherence for oral treatment was assessed by patients using the patient-rated Medication Adherence Questionnaire (MAQ). Data were collected by physicians on patients with a recent acute psychotic episode before switching to long-acting injectable risperidone. Other evaluations included disease severity (Clinical Global Impression - Severity), patients' insight (Positive and Negative Syndrome Scale item G12), treatment acceptance (clinician-rated Compliance Rating Scale), and therapeutic alliance (patient-rated 4-Point ordinal Alliance Scale). Results: A total of 399 psychiatrists enrolled 1,887 patients (mean age 36.8±11.9 years; 61.6% had schizophrenia). Adherence to oral medication was "low" in 53.2% of patients, "medium" in 29.5%, and "high" in 17.3%. Of patients with psychiatrist-rated active acceptance of treatment, 70% had "medium" or "high" MAQ scores (P<0.0001). Medication adherence was significantly associated with therapeutic alliance (4-Point ordinal Alliance Scale score; P<0.0001). Patient age was significantly associated with adherence: mean age increased with greater adherence (35.6, 36.7, and 38.6 years for patients with "low", "medium", and "high" levels of adherence, respectively; P=0.0007), while age <40 years was associated with "low" MAQ classification (P=0.0003). Poor adherence was also associated with a diagnosis of schizophrenia (P=0.0083), more severe disease (Clinical Global Impression - Severity ≥4; P<0.0001), and lower insight (Positive and Negative Syndrome Scale-G12 ≥4; P<0.0001). Conclusion: Self-reported adherence was low in most patients, with a strong positive association between self-reported adherence and psychiatrists' assessment of treatment acceptance. Understanding factors associated with poor medication adherence may help physicians to better manage their patients, thereby improving outcomes. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject.en | long-acting antipsychotic | |
| dc.subject.en | medication adherence | |
| dc.subject.en | schizophrenia | |
| dc.subject.en | therapeutic alliance | |
| dc.title.en | Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone | |
| dc.title.alternative | Patient Prefer Adherence | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.2147/PPA.S89748 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
| dc.identifier.pubmed | 26396505 | en_US |
| bordeaux.journal | Patient Preference and Adherence | en_US |
| bordeaux.page | 1333-1341 | en_US |
| bordeaux.volume | 9 | en_US |
| bordeaux.hal.laboratories | Institut de neurosciences cognitives et intégratives d'Aquitaine (INCIA) - UMR 5287 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-05055693 | |
| hal.version | 1 | |
| hal.date.transferred | 2025-05-05T08:04:36Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | CC BY-NC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Patient%20Preference%20and%20Adherence&rft.date=2015-09-16&rft.volume=9&rft.spage=1333-1341&rft.epage=1333-1341&rft.eissn=1177-889X&rft.issn=1177-889X&rft.au=BAYLE,%20Franck&TESSIER,%20Arnaud&BOUJU,%20Sophie&MISDRAHI,%20David&rft.genre=article |